← Leaderboards
Alison Elizabeth Roth
Portland State University
$2,503,100
Attributed
$5,006,199
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,006,199 · 2
By mechanism
R01$5,006,199 · 2
Top collaborators
- Jane X Kelly4 shared
- Kim C Williamson3 shared
Most similar at Portland State University
Same institution · by research overlap
- Papireddy Kancharla$1,470,310
- Alison Roth$860,762
- Victor Melendez$1,058,418
- Lisa Read$353,819
- Mara Kreishman-Deitrick$357,550
Others in their field
Other Rising Stars on “Plasmodium Falciparum”
- Cindy S Chu · University Of Oxford$3,588,034
- Maria Yazdanbakhsh · Leiden University Medical Center$2,600,040
- Nana Kwaku Minkah · Seattle Children'S Hospital$2,456,734
- Kristin D Lane · Idaho State University$1,564,992
- Papireddy Kancharla · Portland State University$1,470,310
- Caroline Junqueira · Oregon Health & Science University$1,467,454
Research focus
Plasmodium FalciparumIn VitroPlasmodiumChildMalaria InfectionBloodLiverParasitesSporozoitesCessation Of LifeInfectionGenerationsHepatocyteMalariaBioluminescence ImagingGlucosephosphate Dehydrogenase DeficiencyGenome SequencingChemical SynthesisGenomic DnaElectron TransportErythrocytesDrug KineticsDrug InteractionsDrug Resistance
Grant awards (7)
Maturation of human humoral immunity through repeat malaria challenges$778,280
R01 · FY2025 · AI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2025 · AI
Maturation of human humoral immunity through repeat malaria challenges$788,047
R01 · FY2024 · AI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2024 · AI
Maturation of human humoral immunity through repeat malaria challenges$801,244
R01 · FY2023 · AI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2023 · AI
Second-Generation Novel Liver Stage Active Antimalarials$659,657
R01 · FY2022 · AI